Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.

Inclusion Criteria: * Written informed consent, signed and dated by both parents or by the legally acceptable representative(s) of the children, * Child with sickle cell disease, treated with 100 mg and/or 1000 mg Siklos® film-coated tablets at the same daily dose for more than 4 weeks, * Child aged between 2 and 6 years old, * Parents capable of communicating with the investigator and understanding the requirements and constraints of the study protocol and willing to comply with the study requirements, * Children affiliated to a social security plan (including universal health coverage) or beneficiary of a similar insurance plan. Exclusion Criteria: * Participation in any other clinical study for any other pharmaceutical product within 4 weeks preceding study inclusion, * Known hypersensitivity or allergy to the excipients, * Any surgical or medical condition or any significant illness (of which severe hepatic impairment (Child-Pugh classification C), severe renal impairment, toxic ranges of myelosuppression) that, in the opinion of the investigator, constitutes a risk or a contraindication to the participation of the patient to the study, or that may interfere with the objectives, conduct or evaluation of the study.